Monoclonal antibodies to the CD25 (IL-2a) receptors are used for a treatment of:
(Antibodies to CD 25) -Basiliximab reduces the incidence and severity of acute rejection in kidney transplantation without increasing the incidence of oppounistic infections.
Hematological neoplasm
Autoimmune disease
Bone marrow transplantation
Kidney transplant rejection
Acute Kidney Injury